Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) EVP Anni Lotte Kirstine Pedersen sold 20,000 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $263.89, for a total value of $5,277,800.00. Following the completion of the transaction, the executive vice president owned 19,460 shares of the company’s stock, valued at approximately $5,135,299.40. The trade was a 50.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Ascendis Pharma A/S Stock Performance
Shares of NASDAQ:ASND traded down $0.86 during trading on Wednesday, hitting $270.33. 568,089 shares of the company traded hands, compared to its average volume of 703,360. The stock has a market capitalization of $16.86 billion, a price-to-earnings ratio of 17.67 and a beta of 0.40. The business’s fifty day moving average is $242.71 and its 200-day moving average is $240.31. Ascendis Pharma A/S has a one year low of $188.08 and a one year high of $282.15. The company has a quick ratio of 2.29, a current ratio of 2.89 and a debt-to-equity ratio of 0.25.
Wall Street Analyst Weigh In
ASND has been the subject of several research reports. Citigroup reduced their price objective on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating for the company in a research report on Monday, October 26th. Wells Fargo & Company increased their target price on shares of Ascendis Pharma A/S from $326.00 to $330.00 and gave the company an “overweight” rating in a research note on Friday, November 13th. TD Cowen increased their target price on shares of Ascendis Pharma A/S from $341.00 to $352.00 and gave the company a “buy” rating in a research note on Friday, November 13th. Canaccord Genuity Group raised their target price on shares of Ascendis Pharma A/S from $268.00 to $274.00 and gave the stock a “hold” rating in a report on Friday, November 13th. Finally, Weiss Ratings upgraded shares of Ascendis Pharma A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday. Nineteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus price target of $312.67.
Read Our Latest Stock Analysis on Ascendis Pharma A/S
Institutional Trading of Ascendis Pharma A/S
A number of hedge funds have recently bought and sold shares of the company. Chicago Partners Investment Group LLC grew its stake in shares of Ascendis Pharma A/S by 2.3% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 2,316 shares of the biotechnology company’s stock valued at $564,000 after purchasing an additional 52 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 34.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after buying an additional 69 shares during the period. Fifth Third Bancorp lifted its position in shares of Ascendis Pharma A/S by 48.4% during the 3rd quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock worth $64,000 after buying an additional 91 shares during the period. Integrated Wealth Concepts LLC boosted its stake in Ascendis Pharma A/S by 6.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 1,520 shares of the biotechnology company’s stock valued at $346,000 after buying an additional 97 shares in the last quarter. Finally, ProShare Advisors LLC boosted its stake in Ascendis Pharma A/S by 5.6% in the 3rd quarter. ProShare Advisors LLC now owns 2,134 shares of the biotechnology company’s stock valued at $486,000 after buying an additional 113 shares in the last quarter.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.
See Also
- Five stocks we like better than Ascendis Pharma A/S
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
